EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

SGLT2 Inhibitors in Cancer Patients: A Comprehensive Review of Clinical, Biochemical, and Therapeutic Implications in Cardio-Oncology

Alessandra Greco iD, Maria Laura Canale, Vincenzo Quagliariello iD, Stefano Oliva, Andrea Tedeschi iD, Alessandro Inno iD, Marzia De Biasio iD, Irma Bisceglia iD, Luigi Tarantini iD, Nicola Maurea iD, Alessandro Navazio iD, Marco Corda und 4 weitere

International Journal of Molecular Sciences · 16.05.2025 · 26 (10) · 4780

DOI: 10.3390/ijms26104780 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.05.2025. Verfasst von Alessandra Greco und 15 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Division, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Neoplasms, Cardiovascular Diseases. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with active cancer and cancer survivors are at a markedly increased risk for developing cardiovascular comorbidities, including heart failure, coronary artery disease, and renal dysfunction, which are often compounded by the cardiotoxic effects of cancer therapies. This heightened cardiovascular vulnerability underscores the urgent need for effective, safe, and evidence-based cardioprotective strategies to reduce both cardiovascular morbidity and mortality. Sodium-glucose cotransporter 2 inhibitors (SGLT2is), a class of drugs originally developed for the treatment of type 2 diabetes, have demonstrated significant cardiovascular and renal benefits in high-risk populations, independent of glycemic control. Among the currently available SGLT2i, such as empagliflozin, canagliflozin, dapagliflozin, and sotagliflozin, there is growing evidence supporting their role in reducing major adverse cardiovascular events (MACEs), hospitalization for heart failure, and the progression of chronic kidney disease. Recent preclinical and clinical data suggest that SGLT2is exert cardioprotective effects through multiple mechanisms, including the modulation of inflammasome activity, specifically by reducing NLRP3 inflammasome activation and MyD88-dependent signaling, which are critical drivers of cardiac inflammation and fibrosis. Moreover, SGLT2is have been shown to enhance mitochondrial viability in cardiac cells, promoting improved cellular energy metabolism and function, thus mitigating cardiotoxicity. This narrative review critically evaluates the emerging evidence on the cardiorenal protective mechanisms of SGLT2is, with a particular focus on their potential role in cardio-oncology. We explore the common pathophysiological pathways between cardiovascular dysfunction and cancer, the molecular rationale for the use of SGLT2is in cancer patients, and the potential benefits in both primary and secondary prevention of cardiovascular toxicity related to oncological treatments. The aim is to propose a therapeutic paradigm utilizing SGLT2is to reduce cardiovascular mortality, MACE, and the burden of cardiotoxicity in high-risk oncology patients, fostering an integrated approach to cardio-oncology care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsNeoplasmsCardiovascular DiseasesHumansAnimalsCardiotoxicityDiabetes Mellitus, Type 2Cardio-Oncology

Stichwörter der Autor:innen

SGLT2cancercardioprotectioncardiotoxicityinflammationmetabolismpathology

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Cardiology Division, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
  • Cardiology, Versilia Hospital, Azienda USL Toscana Nord-Ovest, 55041 Lido di Camaiore, Italy.
  • Cardiology Division, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, 80145 Naples, Italy.
  • UOSD Cardiologia di interesse oncologico, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
  • Cardiology, "Guglielmo da Saliceto" Hospital, 29121 Piacenza, Italy.
  • Medical Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella, 37024 Verona, Italy.

ORCID-Profile: Alessandra Greco, Vincenzo Quagliariello, Andrea Tedeschi, Alessandro Inno, Marzia De Biasio, Irma Bisceglia, Luigi Tarantini, Nicola Maurea, Alessandro Navazio, Furio Colivicchi, Massimo Grimaldi

Förderung

  • Ministero della Salute

Zitieren

APA

Greco, A., Canale, M. L., Quagliariello, V., Oliva, S., Tedeschi, A., Inno, A., De Biasio, M., Bisceglia, I., Tarantini, L., Maurea, N., Navazio, A., Corda, M., Iacovoni, A., Colivicchi, F., Grimaldi, M., & Oliva, F. (2025). SGLT2 Inhibitors in Cancer Patients: A Comprehensive Review of Clinical, Biochemical, and Therapeutic Implications in Cardio-Oncology. International Journal of Molecular Sciences, 26(10), 4780. https://doi.org/10.3390/ijms26104780

Vancouver

Greco A, Canale ML, Quagliariello V, Oliva S, Tedeschi A, Inno A, et al. SGLT2 Inhibitors in Cancer Patients: A Comprehensive Review of Clinical, Biochemical, and Therapeutic Implications in Cardio-Oncology. International Journal of Molecular Sciences. 2025;26(10):4780. doi:10.3390/ijms26104780

BibTeX
@article{Greco2025,
  author = {Greco, Alessandra and Canale, Maria Laura and Quagliariello, Vincenzo and Oliva, Stefano and Tedeschi, Andrea and Inno, Alessandro and De Biasio, Marzia and Bisceglia, Irma and Tarantini, Luigi and Maurea, Nicola and Navazio, Alessandro and Corda, Marco and Iacovoni, Attilio and Colivicchi, Furio and Grimaldi, Massimo and Oliva, Fabrizio},
  title = {SGLT2 Inhibitors in Cancer Patients: A Comprehensive Review of Clinical, Biochemical, and Therapeutic Implications in Cardio-Oncology},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {10},
  pages = {4780},
  doi = {10.3390/ijms26104780}
}
Kostenlos starten →